AUA 2025 Bladder Cancer

Viewing 1-20 of 58 articles

AUA 2025: Level of Nodal Metastasis in Patients Undergoing Radical Cystectomy and Lymphadenectomy for Muscle-Invasive Urothelial Cancer: Is There Still a Role of Extended Lymphadenectomy in the Post-S1011 Era?

AUA 2025: Upstaging and Risk Migration with Blue Light Cystoscopy for Non-Muscle-Invasive Bladder Cancer: Results from a Prospective Multicenter Registry

AUA 2025: Oncologic Outcomes in Patients Undergoing Radical Cystectomy for NMIBC Following BCG Therapy Failure

AUA 2025: Improving Risk Prediction in Radical Cystectomy Patients Using Artificial Intelligence Models

AUA 2025: Neoadjuvant Therapy with Combined Targeted HER2 and Immunotherapy for T2-T4N0-1M0 Bladder Cancer: A Retrospective Multicenter Study

AUA 2025: Precystectomy ctDNA Burden is Predictive of Poor Oncological Outcomes

AUA 2025: Avelumab First-Line Maintenance in Advanced Urothelial Carcinoma: Conditional Survival and Long-Term Safety in Patients Treated for ≥1 or ≥2 Years in JAVELIN Bladder 100

AUA 2025: Cost-Effectiveness of Nivolumab or Pembrolizumab Versus Surveillance for the Adjuvant Treatment of Patients with High-Risk Muscle Invasive Bladder Cancer

AUA 2025: The First Report of Disease-Free Survival Analyses from the NIAGARA Trial of Perioperative Durvalumab plus Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

AUA 2025: Treatment Outcomes of Enfortumab Vedotin in Ineligible Patients from the EV-301 Trial

AUA 2025: What Constitutes an Optimal TURBT in 2025?

AUA 2025: Bladder Preservation in Patients with Clinical Complete Response to Neoadjuvant Chemotherapy – Ready for Prime Time?

AUA 2025: Should I Use ctDNA to Guide Treatment Decisions Regarding Adjuvant Chemotherapy or IO Therapy after Radical Cystectomy?

AUA 2025: Bladder Cancer Incidence and Plastics-Processing Waste Release in Ohio: Are Microplastics a Novel Risk Factor?

AUA 2025: VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle Invasive Bladder Cancer versus White-light Conventional and Second Resection: the CUT-less Randomized Trial

AUA 2025: Updates to the CORE-008 Trial Protocol: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk Non-Muscle Invasive Bladder Cancer

AUA 2025: Is TMT Really a Valid Option for All My Patients with MIBC

AUA 2025: Active Surveillance for Low-Grade Intermediate Risk Bladder

AUA 2025: Optimal Sequencing: My Patient Has BCG Unresponsive NMIBC and Declines Radical Cystectomy

AUA 2025: Is There a Role for AI in Diagnosis and Risk Stratification for Bladder Cancer?

1
2
3